There are multiple variables were confirmed to be significantly associated with the prognosis of NSCLC with ICI treatment including FGFR4 mutation (P = 0.0209), pathology (P = 0.0055), treatment lines (P = 0.0046), smoking (P = 0.0308), PD-L1 expression (P = 0.0052), and TMB (P = 0.0285) (Fig. 4a–f). The gene discussed is FGFR4; the disease is non-small cell lung carcinoma.